The goal of this proposal is to determine the structure, function, and biological relevance of tenascin in the vascular system. This project is based on the applicants a recent success in the identification of the fibrinogen-like domain of Tenascin-C that promotes adhesion and migration of vascular smooth muscle cells. The applicant has mapped the activity to a peptide located near the C-terminal part of this domain. A novel 6 transmembrane protein which may function as a tenascin receptor was cloned. The structure of this protein displayed strong similarity to the plasma membrane calcium channel gene family of proteins. In addition the applicant has demonstrated that tenascin up regulates the metalloproteinase activity of cultured macrophages and smooth muscle cells. Furthermore, the applicant shows that the epidermal growth factor-like domain of tenascin promotes apoptosis of vascular smooth muscle cells. These findings, together with the action of tenascin in other systems, have prompted new questions about the molecular mechanisms responsible for the full range of tenascin actions.
Aim one will define the ability of the new tenascin binding protein to transport calcium and to determine the distribution of the protein in the vascular system.
Aim 2 will determine the effect of the recombinant Fibrinogen-like domain of tenascin on the formation of neo intimal by using a well-validated rat balloon injury model.
Aim 3 will define the potential consequences of the expression of tenascin in human atheroma by determining its effect on the overall metalloproteinase (MMP) activity of intimal cells and apoptosis of vascular smooth muscle cells. Collectively, these studies are likely to expand our understanding of tenascin in smooth muscle cells.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL050566-07
Application #
6537080
Study Section
Pathology A Study Section (PTHA)
Program Officer
Sopko, George
Project Start
1995-06-01
Project End
2004-05-31
Budget Start
2002-06-01
Budget End
2003-05-31
Support Year
7
Fiscal Year
2002
Total Cost
$306,000
Indirect Cost
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Song, Lei; Wang, Lai; Li, Fuqiang et al. (2017) Bone Marrow-Derived Tenascin-C Attenuates Cardiac Hypertrophy by Controlling Inflammation. J Am Coll Cardiol 70:1601-1615
Wang, Lai; Shah, Prediman K; Wang, Wei et al. (2013) Tenascin-C deficiency in apo E-/- mouse increases eotaxin levels: implications for atherosclerosis. Atherosclerosis 227:267-74
Wang, Lai; Wang, Wei; Shah, Prediman K et al. (2012) Deletion of tenascin-C gene exacerbates atherosclerosis and induces intraplaque hemorrhage in Apo-E-deficient mice. Cardiovasc Pathol 21:398-413
Li, Fuqiang; Tian, Fang; Wang, Lai et al. (2010) Pleiotrophin (PTN) is expressed in vascularized human atherosclerotic plaques: IFN-{gamma}/JAK/STAT1 signaling is critical for the expression of PTN in macrophages. FASEB J 24:810-22
Song, Lei; Wang, Lai; Shah, Prediman K et al. (2010) Bioengineered vascular graft grown in the mouse peritoneal cavity. J Vasc Surg 52:994-1002, 1002.e1-2
Wang, Lai; Sharifi, Behrooz G; Pan, Theresa et al. (2006) Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice. J Am Coll Cardiol 48:1459-68
Sharifi, Behrooz G; Zeng, Zhaohui; Wang, Lai et al. (2006) Pleiotrophin induces transdifferentiation of monocytes into functional endothelial cells. Arterioscler Thromb Vasc Biol 26:1273-80